Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Invivyd's investors include RA Capital Management, Redmile Group, Foresite Capital, Polaris Partners, OrbiMed.
Invivyd is headquartered in Waltham, United States.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Invivyd — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/invivyd. Accessed July 20, 2026.
VCBacked. (2025). Invivyd — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/invivyd
{{cite web |title=Invivyd — Funding & Investors |url=https://www.vcbacked.co/company/invivyd |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated